GO:0061578 K63-linked deubiquitinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061578 defines K63-linked deubiquitinase activity, the enzymatic hydrolysis of ubiquitin chains linked through lysine 63 of ubiquitin.
• This activity is mediated by specialized deubiquitinases (DUBs) such as USP18, USP53, OTUD4, OTUD5, USP33, OTUD1, and USP20 [1,2,3,4,5,6,8].
• K63-linked deubiquitination regulates innate antiviral immunity, inflammatory signaling, mitophagy, and cardiac hypertrophy [1,3,4,6,8].
• Dysregulation of K63-specific DUBs is implicated in diabetic kidney disease, sepsis-associated encephalopathy, and doxorubicin-induced cardiomyopathy [3,5,7].
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable precise interrogation of K63 DUB function in disease contexts [1,2,3,4,5,6,7,8].
• EDITGENE provides end-to-end CRISPR services to accelerate research on K63-linked deubiquitinase activity and its therapeutic potential.
Description
K63-linked deubiquitinase activity (GO:0061578) is a molecular function that specifically removes ubiquitin moieties from proteins modified with Lys63-linked polyubiquitin chains. Unlike K48-linked chains that target proteins for proteasomal degradation, K63-linked chains typically serve non-degradative roles in signal transduction, DNA repair, and immune responses [1,6]. This activity is critical for maintaining cellular homeostasis and is carried out by a subset of deubiquitinating enzymes (DUBs) that exhibit linkage specificity [2,6]. Researchers study K63-linked deubiquitinase activity to understand how cells fine-tune signaling pathways and to identify therapeutic targets for diseases ranging from cancer to neurodegeneration [3,5,7]. The specificity of these enzymes makes them attractive for drug discovery and for dissecting ubiquitin code biology [2,6].
K63-linked deubiquitinase activity At A Glance
| GO ID | GO:0061578 |
|---|---|
| GO term | K63-linked deubiquitinase activity |
| Ontology | molecular_function |
| Synonym | K63-specific deubiquitinase activity, Lys63-specific deubiquitinase activity |
| Major function | Hydrolysis of K63-linked ubiquitin chains from substrate proteins |
| Representative enzymes | USP18, USP53, OTUD4, OTUD5, USP33, OTUD1, USP20 |
| Substrate examples | MAVS, TAK1, PRKN/parkin, MyD88, TRAF2, STAT3 |
| Associated processes | Innate immunity, inflammation, mitophagy, cardiac hypertrophy |
What Is GO:0061578?
K63-linked deubiquitinase activity is defined as the hydrolysis of a ubiquitin unit from a ubiquitinated protein where the ubiquitin chain is linked via the Lys63 residue of ubiquitin. This enzymatic activity reverses K63-linked polyubiquitination, thereby modulating protein-protein interactions and signaling events without directly affecting protein stability [1,6].
Why Is K63-linked deubiquitinase activity Important in Cell Biology?
K63-linked deubiquitinase activity is essential for dynamic regulation of cellular signaling because it reverses non-degradative ubiquitination that controls protein interactions and activation states [1,6]. This activity influences innate antiviral immunity by modulating MAVS aggregation, inflammatory responses through TAK1 and MyD88 [3,6], and mitochondrial quality control via parkin. Dysregulation of K63-specific DUBs contributes to diabetic kidney disease, sepsis-associated encephalopathy, and cardiomyopathy, highlighting their broad pathophysiological relevance [3,5,7]. Understanding this activity at the molecular level offers opportunities for targeted therapeutic intervention [2,8].
• Regulates innate antiviral immunity by controlling MAVS K63-linked polyubiquitination.
• Modulates inflammatory signaling through deubiquitination of TAK1 and MyD88 [3,6].
• Antagonizes parkin-mediated mitophagy by removing K63 chains from PRKN/parkin.
• Protects against diabetic kidney disease by reducing podocyte inflammation.
• Exacerbates sepsis-associated encephalopathy via OTUD1-mediated HK2 release.
• Mediates proteasomal degradation of TRAF2 in doxorubicin-induced cardiomyopathy.
• Ameliorates pathological cardiac hypertrophy by targeting STAT3 deubiquitination.
• Provides a mechanism for linkage-specific regulation of ubiquitin signaling.
• Represents a druggable class of enzymes for therapeutic development [2,6].
• Enables precise CRISPR-based dissection of DUB function in disease models [1,2,3,4,5,6,7,8].
Molecular Mechanism of K63-linked deubiquitinase activity
Substrate Recognition and Linkage Specificity
In simple terms: The enzyme must first find and bind to the correct ubiquitin chain on a target protein.
K63-specific DUBs recognize their substrates through specialized domains that interact with the K63-linked polyubiquitin chain and the target protein [2,6]. For example, OTUD4 is a phospho-activated K63 deubiquitinase that regulates MyD88-dependent signaling, requiring phosphorylation for full activity. USP53 was recently shown to possess intrinsic K63-linkage-directed deubiquitinase activity, with structural features that confer specificity for K63 linkages over other chain types. This specificity ensures that only K63-linked chains are removed, preserving other ubiquitin signals [2,6].
Catalytic Hydrolysis of K63-Linked Ubiquitin Chains
In simple terms: Once bound, the enzyme cuts the ubiquitin chain at the K63 linkage.
The catalytic core of K63-specific DUBs hydrolyzes the isopeptide bond between the C-terminal glycine of one ubiquitin and the epsilon-amino group of Lys63 of the next ubiquitin. This reaction releases free ubiquitin and shortens or removes the K63 chain from the substrate. USP18 promotes K63-linked polyubiquitination of MAVS, but its deubiquitinase activity is not directly involved in this process; instead, USP18 regulates MAVS aggregation through other mechanisms. In contrast, OTUD5 deubiquitinates TAK1 to reduce podocyte inflammation, demonstrating direct catalytic removal of K63 chains.
Regulation by Phosphorylation and Protein Interactions
In simple terms: The activity of these enzymes can be turned on or off by other molecules.
OTUD4 is activated by phosphorylation, which induces a conformational change that enhances its K63 deubiquitinase activity. USP33 deubiquitinates PRKN/parkin and antagonizes its role in mitophagy, and this activity is regulated by cellular context. USP20 ameliorates pathological cardiac hypertrophy by targeting STAT3 deubiquitination, and its expression is enriched in cardiomyocytes. These examples illustrate that K63 DUBs are subject to multiple layers of regulation, including post-translational modifications and tissue-specific expression [4,6,8].
Downstream Signaling Consequences
In simple terms: Removing K63 chains changes how proteins interact and signal.
Deubiquitination of K63 chains can alter protein-protein interactions, localization, and activity [1,6]. For instance, K63-linked polyubiquitination of MAVS is required for its aggregation and antiviral signaling, and USP18 positively regulates this process. OTUD1 promotes HK2 mitochondrial release to drive microglia pyroptosis in sepsis-associated encephalopathy, linking K63 deubiquitination to metabolic reprogramming and cell death. TRAF2 degradation mediated by K63 deubiquitination contributes to mitochondrial dysfunction in doxorubicin-cardiotoxicity. Thus, K63 DUBs serve as critical nodes in diverse signaling networks [1,5,7].
Key Genes Involved in GO:0061578 K63-linked deubiquitinase activity
The following genes encode enzymes or substrates directly implicated in K63-linked deubiquitinase activity, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| USP18 | Positively regulates innate antiviral immunity by promoting K63-linked polyubiquitination of MAVS | Studied in antiviral signaling and immune regulation |
| USP53 | K63-linkage-directed deubiquitinase | Discovery and mechanism of K63-specific DUB activity |
| OTUD5 | Deubiquitinates TAK1 to reduce podocyte inflammation | Diabetic kidney disease and inflammation |
| USP33 | Deubiquitinates PRKN/parkin and antagonizes mitophagy | Mitophagy and Parkinson's disease research |
| OTUD1 | Promotes HK2 mitochondrial release to drive microglia pyroptosis | Sepsis-associated encephalopathy |
| OTUD4 | Phospho-activated K63 deubiquitinase regulating MyD88-dependent signaling | Innate immunity and inflammation |
| TRAF2 | Proteasomal degradation mediated by K63 deubiquitination | Doxorubicin-induced cardiomyopathy |
| USP20 | Targets STAT3 deubiquitination | Pathological cardiac hypertrophy |
| MAVS | Substrate of K63-linked polyubiquitination regulated by USP18 | Antiviral immunity |
| TAK1 | Substrate deubiquitinated by OTUD5 | Podocyte inflammation |
| PRKN/parkin | Substrate deubiquitinated by USP33 | Mitophagy |
| MyD88 | Substrate regulated by OTUD4 | MyD88-dependent signaling |
| STAT3 | Substrate deubiquitinated by USP20 | Cardiac hypertrophy |
| HK2 | Hexokinase 2, affected by OTUD1 | Microglia pyroptosis |
How Is K63-linked deubiquitinase activity Regulated?
K63-linked deubiquitinase activity is regulated at multiple levels. OTUD4 requires phosphorylation for activation, linking its activity to kinase signaling pathways. USP18 expression is induced by interferons and regulates MAVS aggregation, thereby modulating antiviral immunity. USP20 is enriched in cardiomyocytes and its expression is altered in cardiac hypertrophy. Additionally, protein-protein interactions and subcellular localization influence substrate accessibility and catalytic efficiency [2,4]. These regulatory mechanisms ensure that K63 deubiquitination is temporally and spatially controlled [1,2,4,6,8].
K63-linked deubiquitinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| OTUD5 | Diabetic kidney disease | Podocyte-specific knockout or overexpression in mice |
| OTUD1 | Sepsis-associated encephalopathy | Microglia-specific knockout or overexpression |
| USP20 | Pathological cardiac hypertrophy | Cardiomyocyte-specific knockout or transgenic overexpression |
| USP33 | Mitophagy and Parkinson's disease | Neuronal knockout or knock-in of USP33 |
| USP18 | Antiviral immunity | Knockout mice or cell lines infected with viruses |
K63-linked deubiquitinase activity in inflammatory and metabolic diseases
OTUD5 alleviates diabetic kidney disease by deubiquitinating TAK1 and reducing podocyte inflammation and injury. OTUD1 exacerbates sepsis-associated encephalopathy by promoting HK2 mitochondrial release to drive microglia pyroptosis. These findings highlight the role of K63-specific DUBs in inflammatory and metabolic disorders, suggesting that targeting these enzymes could provide therapeutic benefits [3,5].
K63-linked deubiquitinase activity in cardiovascular diseases
USP20 ameliorates pathological cardiac hypertrophy by targeting STAT3 deubiquitination. Proteasomal degradation of TRAF2 mediated by K63 deubiquitination contributes to mitochondrial dysfunction in doxorubicin-induced cardiomyopathy. These studies demonstrate that K63 DUBs are critical regulators of cardiac stress responses and may be exploited for cardioprotection [7,8].
K63-linked deubiquitinase activity in immunity and infection
USP18 positively regulates innate antiviral immunity by promoting K63-linked polyubiquitination of MAVS. OTUD4 is a phospho-activated K63 deubiquitinase that regulates MyD88-dependent signaling, impacting innate immune responses. Dysregulation of these enzymes can lead to impaired pathogen defense or chronic inflammation [1,6].
K63-linked deubiquitinase activity in neurodegeneration and mitophagy
USP33 deubiquitinates PRKN/parkin and antagonizes its role in mitophagy, a process linked to Parkinson's disease and other neurodegenerative disorders. By removing K63 chains from parkin, USP33 modulates mitochondrial quality control, suggesting that K63 DUBs may influence neurodegeneration.
From K63-linked deubiquitinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of OTUD5 affect podocyte inflammation? | OTUD5 knockout podocytes or mice |
| Does OTUD1 promote microglia pyroptosis? | OTUD1 knockout microglia or overexpression |
| Does USP20 regulate STAT3 deubiquitination? | USP20 knockout cardiomyocytes or transgenic mice |
| Does USP33 antagonize parkin-mediated mitophagy? | USP33 knockout neurons or cell lines |
| Does USP18 regulate MAVS aggregation? | USP18 knockout cells or mice |
| Does OTUD4 require phosphorylation for activity? | OTUD4 point mutants (phospho-deficient) |
How to Study the K63-linked deubiquitinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro deubiquitination assay | Catalytic cleavage of K63-linked ubiquitin chains | Enzyme specificity and kinetics |
| Immunoprecipitation and immunoblot | Substrate ubiquitination levels | Cellular signaling studies [1,3,6] |
| Mass spectrometry | Protein interactions and ubiquitination sites | Substrate identification [2,6] |
| CRISPR knockout screening | Gene function in pathways | Discovery of regulators [1,3,4,5,6,7,8] |
| Phospho-specific antibodies | Activation state of DUBs | Signaling regulation |
| Mitophagy flux assays | Mitochondrial clearance | Parkin-mediated mitophagy |
| Echocardiography | Cardiac function | Hypertrophy models |
Biochemical assays for deubiquitinase activity
In vitro deubiquitination assays using recombinant DUBs and K63-linked ubiquitin chains can measure catalytic activity and linkage specificity. These assays often employ fluorescently labeled ubiquitin or mass spectrometry to detect cleavage products. For example, USP53 activity was characterized using such biochemical approaches.
Cell-based ubiquitination assays
Immunoprecipitation followed by immunoblotting with linkage-specific ubiquitin antibodies can assess K63-linked ubiquitination of substrates in cells [1,3,6]. Knockdown or knockout of specific DUBs, followed by substrate ubiquitination analysis, reveals their role in K63 chain removal [1,3,6].
Proteomics and interactomics
Mass spectrometry-based proteomics can identify substrates and interaction partners of K63-specific DUBs [2,6]. Affinity purification of DUB complexes coupled with mass spectrometry has been used to map signaling networks [2,6].
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes that modulate K63-linked deubiquitinase activity or downstream pathways [1,3,4,5,6,7,8]. Such screens are powerful for discovering novel regulators and therapeutic targets [1,3,4,5,6,7,8].
How CRISPR Can Be Used to Study GO:0061578 K63-linked deubiquitinase activity
Knockout
CRISPR knockout of K63-specific DUBs such as OTUD5, OTUD1, USP20, or USP33 enables loss-of-function studies to determine their role in disease models [3,5,8,4]. For example, OTUD5 knockout exacerbates podocyte inflammation in diabetic kidney disease.
Point Mutation
Point mutations can be introduced to abrogate catalytic activity or phosphorylation sites, such as in OTUD4, to dissect mechanism. These models help distinguish enzymatic activity from scaffolding functions.
Knock-in
Knock-in of tagged or mutant DUBs allows for precise tracking and functional analysis in vivo [2,6]. For instance, knock-in of a phospho-deficient OTUD4 mutant can test the importance of phosphorylation.
Overexpression
Overexpression of K63 DUBs such as USP18 or USP20 can reveal gain-of-function phenotypes in antiviral immunity or cardiac hypertrophy [1,8]. These models are useful for validating therapeutic targets [1,8].
How EDITGENE Supports K63-linked deubiquitinase activity Research
Researchers studying K63-linked deubiquitinase activity-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease phenotype. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for K63-linked deubiquitinase activity research.
Frequently Asked Questions About K63-linked deubiquitinase activity
What is K63-linked deubiquitinase activity?
K63-linked deubiquitinase activity (GO:0061578) is the enzymatic hydrolysis of ubiquitin units from proteins modified with Lys63-linked polyubiquitin chains.
What genes are involved in K63-linked deubiquitinase activity?
Key genes include USP18, USP53, OTUD4, OTUD5, USP33, OTUD1, and USP20, which encode enzymes that specifically remove K63-linked ubiquitin chains [1,2,3,4,5,6,8].
How does K63-linked deubiquitination differ from K48-linked deubiquitination?
K63-linked chains are typically non-degradative and regulate signaling, whereas K48-linked chains target proteins for proteasomal degradation [1,6].
What diseases are associated with K63-linked deubiquitinase activity?
Dysregulation is linked to diabetic kidney disease, sepsis-associated encephalopathy, cardiomyopathy, and neurodegenerative disorders [3,5,7,4].
Which deubiquitinase specifically removes K63-linked chains?
USP53 was recently shown to have K63-linkage-directed deubiquitinase activity, and OTUD4 is a phospho-activated K63 deubiquitinase [2,6].
How can I study K63-linked deubiquitinase activity in the lab?
Common methods include in vitro deubiquitination assays, immunoprecipitation, mass spectrometry, and CRISPR knockout models [2,1,3,6].
What is the role of OTUD5 in diabetic kidney disease?
OTUD5 alleviates diabetic kidney disease by deubiquitinating TAK1 and reducing podocyte inflammation and injury.
Does USP18 have K63 deubiquitinase activity?
USP18 positively regulates innate antiviral immunity by promoting K63-linked polyubiquitination of MAVS, but its deubiquitinase activity is not directly involved in this process.
How does OTUD1 contribute to sepsis-associated encephalopathy?
OTUD1 exacerbates sepsis-associated encephalopathy by promoting HK2 mitochondrial release to drive microglia pyroptosis.
What CRISPR models are available for studying K63 DUBs?
EDITGENE offers knockout, point mutation, knock-in, and overexpression models for K63-specific DUBs, as well as CRISPR library screening [1,2,3,4,5,6,7,8].
Conclusion
K63-linked deubiquitinase activity (GO:0061578) is a critical molecular function that regulates diverse signaling pathways by reversing non-degradative ubiquitination. The enzymes responsible, including USP18, USP53, OTUD4, OTUD5, USP33, OTUD1, and USP20, play key roles in immunity, inflammation, mitophagy, and cardiovascular disease [1,2,3,4,5,6,8]. Understanding their mechanisms offers promising avenues for therapeutic intervention. EDITGENE provides advanced CRISPR solutions to accelerate research on these enzymes and their roles in human disease.
References
- 1. Hou J et al.. 2021. USP18 positively regulates innate antiviral immunity by promoting K63-linked polyubiquitination of MAVS.. Nat Commun 12(1):2970 PMID: 34016972
- 2. Wendrich K et al.. 2025. Discovery and mechanism of K63-linkage-directed deubiquitinase activity in USP53.. Nat Chem Biol 21(5):746-757 PMID: 39587316
- 3. Zhao Y et al.. 2024. Podocyte OTUD5 alleviates diabetic kidney disease through deubiquitinating TAK1 and reducing podocyte inflammation and injury.. Nat Commun 15(1):5441 PMID: 38937512
- 4. Niu K et al.. 2020. USP33 deubiquitinates PRKN/parkin and antagonizes its role in mitophagy.. Autophagy 16(4):724-734 PMID: 31432739
- 5. Jing G et al.. 2025. OTUD1 exacerbates sepsis-associated encephalopathy by promoting HK2 mitochondrial release to drive microglia pyroptosis.. J Neuroinflammation 22(1):154 PMID: 40500776
- 6. Zhao Y et al.. 2018. OTUD4 Is a Phospho-Activated K63 Deubiquitinase that Regulates MyD88-Dependent Signaling.. Mol Cell 69(3):505-516.e5 PMID: 29395066
- 7. Dhingra R et al.. 2022. Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy.. Circulation 146(12):934-954 PMID: 35983756
- 8. Zhong L et al.. 2025. Cardiomyocyte-Enriched USP20 Ameliorates Pathological Cardiac Hypertrophy by Targeting STAT3 Deubiquitination.. Adv Sci (Weinh) 12(23):e2416478 PMID: 40192103
